Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04093323
Title Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Recruiting Buffalo New York 14263 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field